Form 4: Zomedica director granted 1.82M SARs

Director Johnny D. Powers received 1,823,107 stock appreciation rights at a $0.1 base price, vesting 11/16/2026 and expiring 11/16/2035.

Summary

• Director Johnny D. Powers reported a grant (Code A) of 1,823,107 Stock Appreciation Rights (SARs) on 11/17/2025.
• The SARs have a base/exercise price of $0.1 per share.
• The award is tied to 1,823,107 underlying shares of common stock.
• The SARs become exercisable on 11/16/2026 and expire on 11/16/2035.
• Post-transaction, 1,823,107 derivative securities are beneficially owned, held directly.
• No non-derivative common shares were reported in this filing.

Sentiment

Score: 5

Explanation: Neutral-to-slightly positive governance signal due to incentive alignment, offset by potential dilution overhang and absence of performance conditions.

Positives

• Equity-based compensation aligns the director’s incentives with shareholders via 1,823,107 SARs.
• Long-dated term (expires 11/16/2035) supports long-term alignment.
• Clear vesting/exercisability date (11/16/2026) provides transparency.

Negatives

• Potential dilution overhang of up to 1,823,107 shares if the SARs are settled in stock.
• No disclosure of performance conditions beyond a time-based exercisability date.
• Exercise/base price set at $0.1 could lead to meaningful value transfer to the insider if the stock appreciates materially.

Future Outlook

No forward-looking statements or guidance provided. The award becomes exercisable on 11/16/2026 and expires on 11/16/2035.

Industry Context

Equity-based awards for directors, including SARs with 10-year terms and time-based exercisability, are common in small- and mid-cap life sciences and animal health companies to align incentives and preserve cash.

Comparison to Industry Standards

• Use of long-term equity awards to directors is consistent with practices at animal health and diagnostics peers (e.g., Zoetis, IDEXX, and legacy Heska) and broader small-cap medtech/biotech firms.
• A 10-year term and one-year-plus time-based exercisability are typical structural features for equity awards across the sector.
• Grant size measured in absolute shares is on the higher side for micro/small-cap issuers, though comparability depends on share price and market cap; SARs help tether value to stock appreciation rather than fixed value.

Related Party Transactions

• Grant of 1,823,107 stock appreciation rights to Director Johnny D. Powers on 11/17/2025.

Stakeholder Impact

• Shareholders: Potential dilution if SARs are settled in shares (up to 1,823,107 underlying shares).
• Directors/Employees: Strengthens equity-based incentive alignment for a board member.
• Company: No immediate cash outlay; future obligation depends on settlement mechanics and stock performance.

Next Steps

• Monitor for vesting on 11/16/2026 and any subsequent exercises or dispositions reported on future Forms 4.
• Track potential share issuance or settlement method at exercise prior to 11/16/2035.

Key Dates

Keywords

Zomedica, ZOMDF, Form 4, insider transaction, stock appreciation rights, SARs, director compensation, derivative securities, vesting, beneficial ownership